2022 Symposium Highlights
The Fourth Annual Hematologic Malignancy Symposium was held March 26, 2022. View the following for information on the past event:
For further information on other Baylor College CPD activities or free online CME activities, email cpd@education.bcm.edu.
Presentation videos (login required):
- David Sallman, M.D.
- Lucy A. Godley, M.D., Ph.D.
- Selina M. Luger, M.D., FRCPC
- Gail J. Roboz, M.D.
- Pierre Fenaux, M.D., Ph.D.
- Elizabeth A. Griffiths, M.D.
- George Vassiliou, M.D., Ph.D.
- Courtney D. DiNardo, M.D., MSCE
- Daniel A. Pollyea, M.D., MS
- Ross L. Levine, M.D.
- Eytan M. Stein, M.D.
- Eric Padron, M.D.
- Amy E. DeZern, M.D., MHS
- Pramila Krishnamurthy, M.D.
- Alexander Perl, M.D.
2021 Symposium Highlights
The Third Annual Hematologic Malignancy Symposium was held March 13, 2021. View the following for information on the past event:
- Videos from Speakers: (onclive.com)
- Symposium Brochure
- Agenda
Symposium Overview
During our third symposium, we brought together national and international acclaimed leukemia scientists to discuss recent advances in clonal hematopoiesis, low/high risk myelodysplastic syndrome, targeted AML therapy with emphasis in novel HMA plus BCL-2 inhibitor combination, advances in P53 myeloid malignancies therapies.
During our 2021 symposium, we incorporated state-of- the-art lectures on post induction HMA treatment, mechanisms of FLT3 inhibition resistance and how to manage elderly AML patients. A highly interactive update on HMA plus BCL-2 inhibitor therapy was followed by a panel discussion on post induction AML maintenance.
Additionally, the symposium provided important novel development in MDS and AML pathogenesis leading to unique opportunity for clinical trial design ideas.
